MyStart Health review

Give the recurring service a defined purpose

MyStart coordinates clinical review, continuing contact and prescription fulfillment. Its programme can be a useful comparison when a reader needs those services together. That purchase should start with an existing weight-care need, rather than an expectation that any weight-loss service constitutes a prevention or longevity programme. ^[1]

The platform says it neither makes treatment decisions nor dispenses medication. Independent licensed clinicians and pharmacies fill those roles. I would want the responsible clinical team and actual pharmacy clear before judging how well this arrangement complements existing care. A single commercial interface does not make those responsibilities interchangeable. ^[1]

Keep the actual outcome in context with the weight, lean-mass and function review.

Judge the full purchase rather than the opening saving

The homepage FAQ starts the programme at $299 per month before discounts, with evaluations, follow-up, prescribed medicine, necessary blood work and shipping described as included. It distinguishes monthly renewal from a three-month charge and supply. The actual formulation, amount supplied and recurring total still need to appear in the selected quote. ^[1]

The base-plan price-lock promise excludes the first-time discount. Meanwhile, the homepage says no membership fees and the refund policy describes a monthly membership supporting users regardless of prescribing. That needs reconciliation; it does not justify adding an imagined second fee or assuming every displayed price buys the same care. ^{[1] [2]}

Put the selected charges and payment periods together in the annual care-cost planner.

A product card does not establish the prescription

The public phone page displays a compounded-tirzepatide starting promotion of $279 against $399, without a clear card interval. Its separate Wegovy and Ozempic cards are followed by a disclosure expressly saying those branded products are not offered. I would not use those cards as evidence of current branded access or a monthly treatment total. ^[4]

The compounded preparations identified in MyStart’s disclosures are not FDA-approved. A reader needs the proposed preparation and reason for selecting it from the clinician, rather than assuming a familiar ingredient name supplies the same evidence as an approved finished medicine. ^[6]

For a separate compounded-care arrangement, read our Sprout Health review.

The refund boundary should be settled before payment

The December 2025 policy provides a specific full-refund exception for medical ineligibility with no prescription issued and no medicine shipped. It separately permits cancellation before pharmacy fulfillment, yet another section excludes refunds if a prescription has been written. That is a meaningful uncertainty before the first payment. ^[2]

After shipment, the policy rejects cancellation, medication returns and refunds; completed or partly completed membership periods are also excluded. The homepage’s cancel-anytime wording should therefore be read as a route to request cancellation, not a universal trial guarantee. Clinical follow-up and future subscriptions need separate attention when care is changing. ^{[1] [2]}

Compare a different membership and refund model in our Zealthy review.

Separate customer stories from clinical evidence

The homepage qualifies its results as a sixteen-customer survey with self-reported experiences that are not typical. That cannot establish preserved function, prevention of disease or longer life from buying this service. It also cannot tell a reader which support package will fit a different medical situation. ^[1]

FDA’s September 9, 2025 warning concerned advertising implying compounded semaglutide was the same as approved medicine. The dated letter does not establish subsequent resolution, contamination or a particular patient outcome. Its relevance is the product-evidence boundary, not a basis for inventing a new clinical safety finding. ^[5]

Keep the product and purpose visible in our service comparisons.

Use continuing contact to solve a real gap

MyStart’s programme FAQ describes access to clinicians and follow-up without an extra consultation charge. That can matter if the arrangement supplies contact a reader would otherwise lack. It does not establish a guaranteed response time, universal availability or a prescription following a preliminary screen. ^[1]

I would compare MyStart once the clinical responsibility, recurring quote and refund cutoff are clear. LifeMD is a separate clinical-access alternative with its own medicine and fee structure. A reader who already has adequate prescribing support may need a narrower pharmacy or cost comparison instead of another ongoing service.

For the separate clinical-access comparison, see our LifeMD review.

Compare a different ongoing clinical-and-behavioral arrangement in our Found review.

For a separate coordinated-care purchase and its longer-plan terms, read our TMates review.

Understanding the cost

Homepage FAQ starts the programme at $299/month before discounts and describes monthly or three-month renewal. Actual selected medicine, supply, promotion and recurring total require a written quote. Separate phone page advertises compounded tirzepatide $279 against $399 without a clear card interval; do not treat that as a monthly complete-care price. Brand-name cards conflict with that page’s express no-Wegovy/no-Ozempic disclosure. Refund cutoff wording conflicts between prescription issuance and fulfillment/shipment. ^{[1] [2] [3] [4]}